High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions

References

• National Cancer Institute Surveillance, Epidemiology and End Results Program. [cited 2017 Jun 20]. https://seer.cancer.gov/statfacts/html/melan.html.
   Google Scholar
• Kaufman HL, Kirkwood JM, Hodu FS, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013;10:588–598.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105–2116.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6:S11–14.
   PubMed Web of Science ®Google Scholar
• Smith FO, Downey SG, Klapper JA, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res. 2008;14:5610–5618.
   PubMed Web of Science ®Google Scholar
• Hughes T, Klairmont M, Sharfman WH, et al. Interleukin-2, ipilimumab, and anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma. Cancer Biol Ther. 2015. [Epub ahead of print]. DOI:10.1080/15384047.2015.1095401.
   PubMedGoogle Scholar
• Kammula US, White D, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer. 1998;83:797–805.
   PubMed Web of Science ®Google Scholar
• Clark JM, Kelley B, Titze J, et al. Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma. Oncology. 2013;84:123–126.
   PubMed Web of Science ®Google Scholar
• Hughes T, Klairmont M, Broucek J, et al. The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunol Immunother. 2015;64:459–465.
   PubMed Web of Science ®Google Scholar
• Alva A, Daniels GA, Wong MK, et al. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother. 2016;65:1533–1544.
   PubMed Web of Science ®Google Scholar
• Payne R, Glenn L, Hoen H, et al. Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program. J Immunother Cancer. 2014;2:13.
   PubMedGoogle Scholar
• Dutcher JP, Schwartzentruber DJ, Kaufman HL, et al. High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014. J Immunother Cancer. 2014;2:26.
   PubMedGoogle Scholar
• Lindsey KR, Rosenberg SA, Sherry RM. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2. J Clin Oncol. 2000;18:1954–1959.
   PubMed Web of Science ®Google Scholar
• Memoli B, De Nicola L, Libetta C, et al. Interleukin-2-induced renal dysfunction in cancer patients reversed by low-dose dopamine infusion. Am J Kidney Dis. 1995;26:27–33.
   PubMed Web of Science ®Google Scholar
• White RL, Schwartzentruber DJ, Guleria A, et al. Cardiopulmonary toxicity of treatment with high-dose interleukin-2 in 199 patients with metastatic melanoma or renal cell carcinoma. Cancer. 1994;74:3212–3222.
   PubMed Web of Science ®Google Scholar
• Webb DE, Austin HA, Belledegrun A, et al. Metabolic and renal effects of interleukin-2 immunotherapy for metastatic cancer. Clin Nephrol. 1988;30:141–145.
   PubMed Web of Science ®Google Scholar
• Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combinationimmune checkpoint blockade. N Engl J Med. 2016;375:1749–1755.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.
   PubMed Web of Science ®Google Scholar
• Buchbinder EI, Gunturi A, Perritt J, et al. A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. J Immunother Cancer. 2016;4:52.
   PubMed Web of Science ®Google Scholar
• Buchbinder EI, Dutcher JP, Perritt JC, et al. A prospective analysis of high-dose interleukin-2 (HD IL-2) following PD-1 inhibitor therapy in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol. 2016;34:e21006.
   Web of Science ®Google Scholar
• Schwartzentrube DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. New Engl J Med. 2011;364:2119–2127.
   PubMed Web of Science ®Google Scholar
• Seung SK, Curti BD, M C, et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2 – tumor and immunological responses. Sci Transl Med. 2012;4:137ra74.
   PubMed Web of Science ®Google Scholar
• Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005;12:1005–1016.
   PubMed Web of Science ®Google Scholar
• Prieto PA, Yang JC, Sherry RM, et al. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012;18:2039–2047.
   PubMed Web of Science ®Google Scholar
• Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science. 1976;193:1007–1008.
   PubMed Web of Science ®Google Scholar
• Liao W, Lin J-X, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity. 2013;38:13–25.
   PubMed Web of Science ®Google Scholar
• Lenardo M, Chan KM, Hornung F, et al. Mature T lymphocyte apoptosis - immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol. 1999;17:221–253.
   PubMed Web of Science ®Google Scholar
• Skrombolas D, Frelinger JG. Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy. Expert Rev Clin Immunol. 2014;10:207–217.
   PubMed Web of Science ®Google Scholar
• Charych DH, Hoch U, Langowski JL, et al. NKTR-214, an engineered cytokine with biased IL2 receptor binding, increased tumor exposure, and marked efficacy in mouse tumor models. Clin Cancer Res. 2016;22:680–690.
   PubMed Web of Science ®Google Scholar
• Sabatino M, Kim-Schultze S, Panelli MC, et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol. 2009;27:2645–2652.
   PubMed Web of Science ®Google Scholar
• Weiss GR, Grosh WW, Chianese-Bullock KA, et al. Molecular insights on the peripheral and intratumoral effect sof systemc high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res. 2011;17:7440–7450.
   PubMed Web of Science ®Google Scholar
• Jamieson NB, Maker AV. Gene expression profiling to predict responseiveness to immunotherapy. Cancer Gene Ther. 2017;24:134–140.
   PubMed Web of Science ®Google Scholar